Acerus Files a New Drug Submission for GYNOFLOR™ in Canada

07:30 EST 1 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Acerus Pharmaceuticals Corporation (TSX:ASP) today announced that it has filed a New Drug Submission (NDS) for GYNOFLOR™ with Health Canada. GYNOFLOR™ is an ultra-low dose estrogen (estriol) and probiotic (Lactobacillus acid...

Other Sources for this Article

Acerus Pharmaceuticals Corporation
Tricia Symmes, 289-327-1499
Chief Operating Officer


More From BioPortfolio on "Acerus Files a New Drug Submission for GYNOFLOR™ in Canada"

Quick Search


Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

The menopause is a natural event for all women; the ovaries no longer produce estrogen and progesterone. This can be due to natural aging (usual age of onset is 51 years), or through chemotherapy and surgery on the ovaries. The changing balance of the ho...